Seedfunders’ Post

🏥 Big strides for SPRY Therapeutics! The SaaS platform for physical therapy professionals has raised $15 million in a new funding round led by Flourish Ventures, Together Fund, and Fidelity's Eight Roads & F-prime Capital, bringing its total funding to $25 million since its 2021 launch. Co-founded by Brijraj Bhuptani (former CTO of Ola) and Riyaz Rehman, SPRY is transforming clinic management by automating complex billing processes and enhancing patient engagement. With this new funding, SPRY is set to expand further into the US market and continue revolutionizing physical therapy management! 🚀💡 #HealthTech #SaaS #Funding #Innovation #SPRY #iAccelerate

🚨 Price tag scoop: InTandem Capital Partners' @Vivo Infusion acquires Infusion Associates for between $180M-$200M, sources told me. Why it matters: Similar to clinical trial site management, the fragmented infusion market has been a bright spot in health care investing for PE. What I’m watching: IVX, backed by Great Hill since 2021, and Pure Infusion, backed by Frazier since 2019, are both ripe for a change of hands given the momentum in the sector. Carousel Capital-backed Palmetto was on the block in 2022 before the process was shelved — now could be a good time for the asset to come back to market. Get more exclusive information such as combined EBITDA and current revenue figure for the business below 👇 #privateequity #infusion #infusionassets #mergersandacquisitions

Funding News: Spry Therapeutics Raises $15 Million! Spry Therapeutics, a SaaS platform transforming physical therapy, has secured $15 million in a funding round led by Flourish Ventures, Together Fund, and Fidelity’s Eight Roads and F-Prime Capital. This brings the total funding to $25 million since its launch in 2021. 🌟 About Spry Therapeutics: # Founded: By Brijraj Bhuptani and Riyaz Rehman. # Focus: Automating clinic management for physical therapy professionals, including complex billing, patient engagement, and data management. # Growth: In just 18 months, SPRY has partnered with 105+ clinics across 30 states in the US, earning recognition as the top physical therapy software solution by G2. 💼 Expansion Plans: The fresh capital will fuel SPRY's expansion in the US market, helping clinics manage insurance reimbursements, cash flow, and improve overall operational efficiency. With a rapidly growing footprint, SPRY is set to redefine how physical therapy practices operate, offering advanced solutions compared to competitors like WebPT and Prompt Therapy Solutions Inc . At Aspirants Space (https://lnkd.in/gYkc-Ni8), we’re excited to see how SPRY is revolutionizing physical therapy. Tag someone interested in health tech or clinic management to join the journey! #AspirantsNews #SPRYTherapeutics #Funding #HealthTech #SaaS #PhysicalTherapy #Growth #TechTalent

📈What If #woundcare was a mutual fund... Last week, I initiated a conversation on this topic, and the discussion and direct follow-ups were fantastic. 💬   Imagine evaluating the wound care industry as a stock fund — its hypothetical value I would place at $66.98 per share. This "stock" experienced a 7% decline vs 2022, and represents revenue of approximately $12.4 billion from wound-related sectors across various indices including Nasdaq, NYSE, OTC, and Australian exchanges (adjusted to USD). This concept fund covers wound care biologics, synthetics, advanced dressings, and cutting-edge technologies such as AI. Notably, it excludes lower extremity hardware, orthopedic elements, and companies focusing on chronic diseases like diabetes (for instance, Medtronic, for now). Publicly traded companies in this analysis include MiMedx, Organogenesis, Convatec, Integra LifeSciences, 3M, Smith+Nephew, Coloplast, PolyNovo Limited, AVITA Medical, Sanara MedTech, Celularity Inc., Aroa Biosurgery Limited, Spectral AI and Next Science. What might have caused the 7% decline, and do you agree with the $66.98 valuation? Updates are expected as Coloplast incorporates Kerecis into reporting, impacting revenue percentages for wound care, and as 3M undergoes its spinoff into Solventum. Anyone attending the J.P. Morgan Healthcare meeting – would love to hear from you (Karen Cross, Fertram Sigurjonsson, others?) Preston Alexander - would love your take on this approach given your background and serious finance skills. SmartTRAK / BioMedGPS, LLC and Susan Paquette - what do you think?   I'm curious what physicians think about analyzing the industry with this approach - David Armstrong, Brian D. Lepow, Alton R. Johnson Jr., DPM, DABPM, FACPM, FASPS, CWSP Others with unique perspectives - would love your input here; Joe McClung, Matt Kaufman, Greg VanDyne, Santino Costanzo, Patrick Cheng Looking forward to a deeper dive into the space and continuing the dialogue. I'm happy to share the tables I built developing the model and approach - just let me know.

Moximed closed a Series D preferred stock financing worth up to $91 million. The funding round includes $61 million and an option to close on up to an additional $30 million. 👏 ⭐ Elevage Medical Technologies, a Patient Square Capital platform, led the round. New investors Cormorant Asset Management, LP and Warren Point Capital joined in the funding. Existing investors New Enterprise Associates (NEA), Future Fund, Advent Life Sciences, Gilde Healthcare, Vertex Ventures HC, GBS Venture Partners and MORGENTHALER VENTURE PARTNERS IX LP all participated. 💬 “This financing is validation of the significant market opportunity for the MISHA Knee System,” said Christopher Gleason, President and CEO of Moximed. 🔗 Learn more: https://lnkd.in/djdDtwkt #MedicalDevice #MedTech #MedicalEquipment #HealthTech #Knee #Orthopaedics #MedicalDevices #Medicine #TechNews #Funding #MedTechFunding #FundingRound #AngelInvestment #GSCapitalConnect

PatientFi, a company offering medical practices a comprehensive technology suite of payment and subscription solutions to help patients pay for elective procedures, today announces the closing of a significant growth equity financing led by new investor Questa Capital, a venture growth equity firm focused on expansion-stage healthcare companies, with participation from the company’s existing investors. PatientFi intends to use the proceeds to cement its position as a market leader in its core specialties for elective healthcare practices and their patients. The growth capital will be used primarily for accelerating sales and marketing, developing new commercial partnerships, and launching new product initiatives. Read more: https://lnkd.in/dqpAdqpA Todd Watts #fundraising #funding #fintech #finance #FinancialIT

#Update Spry Therapeutics, a SaaS platform for physical therapy professionals, has raised $15 million in funding. The funds will be used to accelerate SPRY's expansion in the US market. Spry Therapeutics's AI-driven platform automates complex billing tasks, streamlines clinic operations, and boosts efficiency for physical therapists. The company aims to transform physical therapy by addressing key business challenges and improving patient outcomes. Read the story: https://ow.ly/r6k950THJgT Flourish Ventures, Together Fund, Fidelity’s Eight Roads, F-Prime Capital, Ola #SPRYTherapeutics #SaaSPlatform #PhysicalTherapy #FundingNews #HealthTech #AIinHealthcare #ClinicOperations #PatientOutcomes #BusinessChallenges #USMarketExpansion

Shares in Verici Dx PLC (AIM:VRCI), a company developing tests to understand how patients respond to organ transplants, fell 13.5% to 8.65p after it raised £5.5 million in a discounted placing. The AIM-listed firm, which agreed to issue new ordinary shares at 9p apiece, a discount of 11.1% to its last closing mid-price, said it also plans to raise further cash via a retail offer on the BookBuild platform, which it will announce shortly. With these funds, Verici plans to enhance its bioinformatics capabilities, accelerate market development, and further validate its product initiatives, including the post-transplant test Tutivia. More at #Proactive #ProactiveInvestors #AIM #VRCI #VericiDx #DiagnosticInnovation #HealthcareTechnology #PrecisionMedicine http://ow.ly/GuXP105b1MF

👋 Today, we welcome Shape Memory Medical to our Health portfolio! Our Earlybird Health team led the company's USD 38 M Series C financing with the participation of new and existing investors, including HBM Partners AG, Wexford Capital LP, MedFocus Fund, and Emergent Medical Partners. Shape Memory Medical develops innovative therapeutic solutions with its proprietary shape memory polymers for endovascular applications, addressing conditions such as abdominal aortic aneurysm (AAA). Its devices are approved in over 25 countries spanning regions in Asia, the Middle East, Europe, the Americas, and Australia. 🔬 “Shape Memory Medical’s approach to embolization is highly differentiated. At Earlybird Health, we support companies with breakthrough technologies and robust, positive patient outcomes. With 35 million people worldwide affected by AAA, leading to 150,000-200,000 annual deaths due to rupture, Shape Memory Medical’s innovative concepts for managing aortic aneurysms have the potential to be transformative in treating this condition,” comments Partner Thom Rasche. 👀 Find the press release at: https://bit.ly/48DcuE3 With: Edward (Ted) Ruppel, Mary Dennehy, John Yianni, Dr. Christoph Massner, Junkai Z. #EBVCgang #Healthcare #AAA #SeriesC #Startups

DarioHealth , the pioneering digital therapeutics platform hailing from Israel, continues to make waves in the industry. Established in 2011, DarioHealth has been at the forefront of delivering evidence-based interventions for chronic conditions. In a strategic move that underscores its commitment to innovation and growth, DarioHealth has just unveiled its acquisition of Twill, another prominent Digital Health venture. The deal, valued at $10 million upfront, alongside an additional $10 million in stock, with potential worth reaching upwards of $20 million, signifies a significant step forward for both companies. DarioHealth's leadership has articulated that this acquisition marks a pivotal moment, consolidating the strengths of both platforms to offer one of the most comprehensive digital solutions for chronic diseases and mental health in the market. They anticipate that pro forma earnings for 2023 are set to nearly double, with projected margins soaring above 80% by 2025. This strategic alignment also presents an opportunity to streamline costs, potentially reducing expenditures by almost a third. Curious about what exactly DarioHealth has acquired? Allow us to introduce Twill with a brief profile, shedding light on the synergies and innovations that lie ahead. #digitalhealth #acquisition #consolidation